HSA
CRSP icon

Hussman Strategic Advisors’s CRISPR Therapeutics CRSP Stock Holding History

Hussman Strategic Advisors’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-9,300
Closed -$422K – 243
2023
Q3 		$422K Hold
9,300
– – 0.08% 250
2023
Q2 		$522K Sell
9,300
-7,300
-44% -$414K 0.1% 248
2023
Q1 		$751K Hold
16,600
– – 0.12% 241
2022
Q4 		$675K Buy
16,600
+6,200
+60% +$329K 0.11% 239
2022
Q3 		$680K Sell
10,400
-10,400
-50% -$754K 0.12% 235
2022
Q2 		$1.26M Buy
20,800
+10,400
+100% +$611K 0.22% 168
2022
Q1 		$653K Hold
10,400
– – 0.13% 228
2021
Q4 		$788K Sell
10,400
-2,000
-16% -$175K 0.17% 190
2021
Q3 		$1.39M Buy
12,400
+3,100
+33% +$389K 0.31% 130
2021
Q2 		$1.51M Buy
9,300
+5,700
+158% +$693K 0.31% 128
2021
Q1 		$439K Sell
3,600
-6,600
-65% -$997K 0.09% 270
2020
Q4 		$1.56M Sell
10,200
-20,400
-67% -$2.41M 0.41% 97
2020
Q3 		$2.56M Buy
30,600
+15,250
+99% +$1.35M 0.68% 32
2020
Q2 		$1.13M Hold
15,350
– – 0.29% 138
2020
Q1 		$651K Buy
15,350
+5,100
+50% +$263K 0.18% 198
2019
Q4 		$624K Buy
+10,250
New +$560K 0.2% 160

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Hussman Strategic Advisors's CRSP Position: Q4 2023 in Review

Hussman Strategic Advisors sold out of CRISPR Therapeutics (CRSP) in Q4 2023, closing a stake of 9,300 shares — an estimated $422K sold.

Hussman Strategic Advisors first reported a position in CRSP in Q4 2019 and held it in 16 quarters. The position peaked at $2.56M in Q3 2020. 472 funds tracked by Wall St. Rank hold CRSP as of Q4 2023.

  • Hussman Strategic Advisors reported no remaining CRISPR Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Hussman Strategic Advisors sold 9,300 CRISPR Therapeutics shares in Q4 2023, an estimated $422K.
  • Hussman Strategic Advisors first reported a position in CRISPR Therapeutics in Q4 2019 and held it in 16 quarters.
  • Hussman Strategic Advisors's CRISPR Therapeutics position peaked at $2.56M in Q3 2020.
  • 472 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q4 2023.

Based on Hussman Strategic Advisors's 13F filing for Q4 2023, filed 1 Feb 2024.